124 Views | 29 Downloads
Gregory B. Lesinski Ph.D., MPH, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Road NE, Atlanta, GA 30322, Phone: 404-778-3072. Email: gregory.b.lesinski@emory.edu
GBL, BFE, and SS conceptualized this project and obtained funding for the execution. MRF and TAM generated the raw data for each figure. BO, TB, AN, CM, WS, CW, BFE, and SS conducted the clinical work associated with this trial. CJH, YT, and ZL analyzed the data. CJH wrote the original draft. All authors participated in revisions of the manuscript.
The authors are grateful for all the patients and families who participated in this clinical trial. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
MRF, CJH, YT, ZL, AN, CM, and TAM have no conflicts of interest to declare. BO has consulted for Genentech, Amgen, and Merck. The terms of these arrangements have been reviewed and approved by Indiana University in accordance with its conflict-of-interest policies. TBS has consulted for Ipsen, Array Biopharma, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, and Merck through his institution. TBS has also consulted for Boehringer Ingelheim, Janssen, Eisai, Daichii Sankyo, Natera, TreosBio, Celularity, Exact Science, and Sobi and has been compensated for these services. TBS has received research funding from Agios, Arys, Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Array Biopharma, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and BMS. The terms of these arrangements have been reviewed and approved by Mayo Clinic in accordance with their conflict-of-interest policies. WS has received honoraria from Merck, BMS, Lexicon, Mylan, Ipsen, Blueprint Medicine, Signatera, and Exilexis. Dr. Shaib has also received research support from Lexicon, Eli Lilly, and GSK. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. CW has consulted for Natera and Array Biopharma as well as received clinical trial funding from Vaccinex, Rapt Therapeutics, INBHRX, Boston Biomedical Inc., Seattle Genetics, Lycera, and Symphogen. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. BFE has consulted for Ipsen, Merck and Co., Bayer, AstraZeneca, Bristol-Myers Squibb, Inc. and been a speaker for Lexicon, Inc. He serves as a consultant to Merck and Co., and receives compensation for these services. He has also received research funding through a sponsored research agreement between Emory University and Bristol-Myers Squibb, Boston Biomedical, Novartis, Merck and Co, Bayer, Exelixis, Pfizer, AstraZeneca/Medimmune, Incyte, and EUSA. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. SS is currently employed by Eli Lilly. GBL has consulted for ProDa Biotech, LLC and received compensation. He has also received research funding through a sponsored research agreement between Emory University and Merck and Co., Bristol-Myers Squibb, Boerhinger-Ingelheim, and Vaccinex. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies.
Research funding for the clinical trial and correlative research studies was provided to investigators through a sponsored research agreement between Merck and Co., Inc and Emory University or The Ohio State University.
Research reported in this publication was supported in part by the Cancer Tissue and Pathology shared resource and the Pediatrics/Winship Flow Cytometry Core of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292.